X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON LTD ALKEM LABORATORIES/
BIOCON LTD
 
P/E (TTM) x - 75.4 - View Chart
P/BV x 7.4 7.1 104.1% View Chart
Dividend Yield % 0.6 0.2 335.9%  

Financials

 ALKEM LABORATORIES   BIOCON LTD
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON LTD
Mar-17
ALKEM LABORATORIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,5891,162 136.8%   
Low Rs1,232483 255.3%   
Sales per share (Unadj.) Rs417.5194.6 214.6%  
Earnings per share (Unadj.) Rs56.334.4 163.6%  
Cash flow per share (Unadj.) Rs64.748.3 134.1%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.1 740.3%  
Book value per share (Unadj.) Rs292.9241.9 121.1%  
Shares outstanding (eoy) m119.57200.00 59.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.2 80.0%   
Avg P/E ratio x25.123.9 104.8%  
P/CF ratio (eoy) x21.817.0 128.0%  
Price / Book Value ratio x4.83.4 141.7%  
Dividend payout %22.62.9 776.2%   
Avg Mkt Cap Rs m168,653164,440 102.6%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m9,1717,470 122.8%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m49,91538,911 128.3%  
Other income Rs m1,6451,571 104.7%   
Total revenues Rs m51,56140,482 127.4%   
Gross profit Rs m8,4829,795 86.6%  
Depreciation Rs m1,0062,772 36.3%   
Interest Rs m671260 257.9%   
Profit before tax Rs m8,4518,334 101.4%   
Minority Interest Rs m-114163 -69.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,616 99.4%   
Profit after tax Rs m6,7316,881 97.8%  
Gross profit margin %17.025.2 67.5%  
Effective tax rate %19.019.4 98.0%   
Net profit margin %13.517.7 76.3%  
BALANCE SHEET DATA
Current assets Rs m27,06240,477 66.9%   
Current liabilities Rs m15,32416,783 91.3%   
Net working cap to sales %23.560.9 38.6%  
Current ratio x1.82.4 73.2%  
Inventory Days Days6760 111.6%  
Debtors Days Days4183 49.8%  
Net fixed assets Rs m12,61045,073 28.0%   
Share capital Rs m2391,000 23.9%   
"Free" reserves Rs m34,49047,377 72.8%   
Net worth Rs m35,02748,377 72.4%   
Long term debt Rs m1,21221,082 5.7%   
Total assets Rs m54,38793,942 57.9%  
Interest coverage x13.633.1 41.2%   
Debt to equity ratio x00.4 7.9%  
Sales to assets ratio x0.90.4 221.6%   
Return on assets %13.67.6 179.0%  
Return on equity %19.214.2 135.1%  
Return on capital %24.912.6 197.2%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56312,988 50.5%   
Fx outflow Rs m3,0127,899 38.1%   
Net fx Rs m3,5525,089 69.8%   
CASH FLOW
From Operations Rs m7,2596,400 113.4%  
From Investments Rs m1,864-4,985 -37.4%  
From Financial Activity Rs m-9,273-1,775 522.4%  
Net Cashflow Rs m-150-473 31.7%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 20, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS